Eupraxia Pharmaceuticals Inc experienced a decline in stock price this week amidst recent fundraising efforts and ongoing clinical developments.
Eupraxia Pharmaceuticals Inc (EPRX.TO) has seen its stock price fluctuate recently, with a notable drop of 3.91% today, bringing its weekly performance to a decrease of 2.05%. As a clinical-stage biotechnology company, Eupraxia focuses on developing innovative treatments for unmet medical needs, leveraging its proprietary Diffusphere™ technology. This week, the company has been in the headlines due to its recent public offering and financial updates, which may have influenced investor sentiment.
Investor takeaway: Investors should consider the implications of Eupraxia's recent public offering and its ongoing clinical trials while evaluating the stock's performance and future potential.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Eupraxia Pharmaceuticals Inc
EPRX.TO
EPRX.TO
Eupraxia Pharmaceuticals Inc
WealthAwesomeMarket cap
$586.64M
52W high
$12.86
52W low
$6.94
1W change
+6.67%
Beta
1.50
Analyst Price Targets
Based on analyst covering EPRX
Wall Street analysts forecast EPRX stock price to rise 79.1% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$16.33
+79.1% Upside
Current Price
C$9.12
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EPRX's historical volatility
30-Day Vol
58.3%
Annualized
90-Day Vol
57.5%
Annualized
Trend (90d)
-49.1%
Annualized drift
90d Mean
C$7.65
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$8.60 | C$7.04 – C$10.52 |
| 60 trading days | C$8.11 | C$6.11 – C$10.78 |
| 90 trading days | C$7.65 | C$5.40 – C$10.84 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Eupraxia Pharmaceuticals Inc has a market cap of approximately C$618 million.
The stock is currently trading at C$8.91, significantly below its 50-day and 200-day moving averages of C$9.46 and C$9.69, respectively.
Bull case
Eupraxia's recent public offering raised approximately US$55 million, providing the company with essential funds to support clinical trials and advance its lead product, EP-104GI. Analysts are optimistic, with an average target price indicating significant upside potential.
Bear case
Despite the positive outlook from analysts, the stock has shown volatility and is currently trading below its moving averages, which may signal challenges ahead. The company's negative profit margin and return on equity could also raise concerns among investors.
Recent Price Action
Advertisement
Eupraxia Pharmaceuticals Inc's stock closed at C$8.91, reflecting a decrease of 3.91% on the day and a 2.05% drop over the week. The stock has experienced a year-to-date decline of 13.10%, despite a 7.57% increase over the past month. This performance indicates some volatility and investor caution surrounding the stock.
Company News and Catalysts
This week, Eupraxia Pharmaceuticals announced the successful pricing of a public offering aimed at raising approximately US$55 million. The offering included 6,428,574 common shares priced at US$7.00 per share, along with pre-funded warrants to purchase additional shares. Following this, the company completed the offering, closing with gross proceeds of approximately US$63.2 million, which includes the full exercise of the underwriter's option. These financial moves aim to bolster the company's resources for ongoing clinical trials, particularly for its lead program, EP-104GI.
Technical Picture
Currently, Eupraxia Pharmaceuticals is trading below its key moving averages, with the 50-day moving average at C$9.46 and the 200-day moving average at C$9.69. The stock has a 52-week trading range of C$6.41 to C$12.86, indicating it is currently at 39% of its range. With a beta of 1.50, the stock is more volatile than the market, which may lead to significant price fluctuations. The latest trading volume was 92,199 shares, compared to the 20-day average volume of 80,313 shares, suggesting increased trading activity.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
